Abingdon Health to work with Centre for Process Innovation to support early-stage innovators

York firm Abingdon Health has announced that it has signed a memorandum of understanding with the Centre for Process Innovation (CPI).

Abingdon Health, which specialises in the development and manufacturing of medical diagnostic tests, said the signing would see the organisations explore opportunities to collaborate across the medical technology sector.

The CPI is a British technology and innovation social enterprise which works to help companies develop, prove and scale new products.

Speaking on the signing, Chris Hand, executive chairman of Abingdon Health, said: “Through this partnership with CPI, we can engage with promising technologies earlier in their journey and provide a seamless route to product verification, regulatory approval and scalable manufacture.

Dr Chris Hand, executive chairman of Abingdon Health.placeholder image
Dr Chris Hand, executive chairman of Abingdon Health.

“Together, we are creating a compelling proposition for companies looking to bring innovative healthcare solutions to market.”

Abingdon said that under the memorandum of understanding, CPI and Abingdon will work together to identify opportunities where CPI can support innovators during the early phases of technology development, proof of concept, prototyping and process development.

Programmes may then be transitioned to Abingdon Health for product verification, validation, regulatory support and scalable manufacturing.

Anthony Celli, commercial director of CPI, said: "The UK and US are home to world-class MedTech innovation, but many developers face challenges when moving from technology development to commercial manufacturing and regulatory approval.

“By combining CPI’s expertise in technology development and scale-up with Abingdon Health’s proven capabilities in manufacturing, validation and regulatory support, we can provide innovators with a clearer pathway to market and help accelerate the delivery of transformative healthcare technologies."

Announcing its annual results last month, Abingdon Health posted total revenues of £11.3m for the year ended 30 June, up 32 per cent on the year prior.

The company also narrowed its pre-tax losses during the year, posting a loss of £2m for the period against £3.5m the previous year.

The results came during a year which saw Abingdon Health launch a new facility in the US and list on the US-based OTCQB Venture Market.

The firm said the new site represents a “significant step forward” for its US operations, providing it with the “infrastructure and capacity to expand its US footprint and respond to growing demand”

Related topics:
News you can trust since 1754
Follow us
© 2026 Iconic Media Group Ltd. All rights reserved.Cookie SettingsTerms and ConditionsPrivacy notice